ScinoPharm Taiwan (神隆) announced on the 21st that its Bortezomib injection for Multiple Myeloma has been granted a drug license by the Taiwan Food and Drug Administration (TFDA). This follows the product’s 2023 US FDA approval and marks ScinoPharm’s first injectable drug to be authorized for the Taiwan market.

• Standard of Care: Bortezomib is a proteasome inhibitor and a Category 1 recommended therapy under NCCN guidelines. It is also listed as an "Essential Medicine" for targeted therapy by the TFDA.
• Market Need: In Taiwan, approximately 700–800 new cases of Multiple Myeloma are diagnosed annually, primarily among the elderly.
• Strategic Shift: CEO Dr. Lilian Lu noted that while ScinoPharm has historically focused on international markets (with four ANDAs currently held in the US), the company is now actively localizing its high-quality, FDA-approved pipeline to support Taiwan’s national drug supply resilience. ScinoPharm will proceed with applications for National Health Insurance (NHI) reimbursement pricing.

Resource: 神隆多發性骨髓瘤治療藥物Bortezomib 繼美國之後再度獲得台灣藥證